Elevated β-catenin activity contributes to carboplatin resistance in A2780cp ovarian cancer cells

Biochemical and Biophysical Research Communications

Volumn 468, Issue 1-2, 2015, Pages 173-178

  Barghout, Samir H ^a   Zepeda, Nubia ^a   Xu, Zhihua ^a   Steed, Helen ^a   Lee, Cheng Han ^a   Fu, Yangxin ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Carboplatin; Chemoresistance; Epithelial ovarian cancer; Wnt catenin

Indexed keywords

BETA CATENIN; CARBOPLATIN; CISPLATIN; GLYCOGEN SYNTHASE KINASE 3; PROTEIN INHIBITOR; WNT PROTEIN; ANTINEOPLASTIC AGENT;

A2780CP CELL LINE; ARTICLE; CANCER RESISTANCE; CELL LYSATE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; EXON; FEMALE; HUMAN; HUMAN CELL; IC50; OVARIAN CANCER CELL LINE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN LOCALIZATION; TRANSCRIPTION REGULATION; WNT SIGNALING PATHWAY; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; METABOLISM; NEOPLASMS, GLANDULAR AND EPITHELIAL; NUCLEOTIDE SEQUENCE; OVARIAN NEOPLASMS; OVARY; TRANSCRIPTION INITIATION; TUMOR CELL LINE; UPREGULATION;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BETA CATENIN; CARBOPLATIN; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; EXONS; FEMALE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OVARY; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION; WNT SIGNALING PATHWAY;

EID: 84947758099     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.10.138     Document Type: Article

References (44)

1. G.C. Jayson, E.C. Kohn, H.C. Kitchener, and J.A. Ledermann Ovarian cancer Lancet 384 2014 1376 1388
2. D. Jelovac, and D.K. Armstrong Recent progress in the diagnosis and treatment of ovarian cancer CA Cancer J. Clin. 61 2011 183 203
3. R. Agarwal, and S.B. Kaye Ovarian cancer: strategies for overcoming resistance to chemotherapy Nat. Rev. Cancer 3 2003 502 516
4. R.C. Bast Jr., B. Hennessy, and G.B. Mills The biology of ovarian cancer: new opportunities for translation Nat. Rev. Cancer 9 2009 415 428
5. J.K. Van Camp, S. Beckers, D. Zegers, and W. Van Hul Wnt Signaling and the Control of Human Stem Cell Fate Stem Cell Rev. 10 2014 207 229
6. F. Takahashi-Yanaga, and M. Kahn Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin. Cancer Res. 16 2010 3153 3162
7. R.C. Arend, A.I. Londono-Joshi, J.M. Straughn Jr., and D.J. Buchsbaum The Wnt/beta-catenin pathway in ovarian cancer: a review Gynecol. Oncol. 131 2013 772 779
8. C.M. Lee, H. Shvartsman, M.T. Deavers, S.C. Wang, W. Xia, R. Schmandt, D.C. Bodurka, E.N. Atkinson, A. Malpica, D.M. Gershenson, M.C. Hung, and K.H. Lu beta-catenin nuclear localization is associated with grade in ovarian serous carcinoma Gynecol. Oncol. 88 2003 363 368
9. H. Wang, M.S. Makki, J. Wen, Y. Dai, Q. Shi, Q. Liu, X. Zhou, and J. Wang Overexpression of beta-catenin and cyclinD1 predicts a poor prognosis in ovarian serous carcinomas Int. J. Clin. Exp. Pathol. 7 2013 264 271
10. M. Saegusa, and I. Okayasu Frequent nuclear beta-catenin accumulation and associated mutations in endometrioid-type endometrial and ovarian carcinomas with squamous differentiation J. Pathol. 194 2001 59 67
11. R. Wu, Y. Zhai, E.R. Fearon, and K.R. Cho Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas Cancer Res. 61 2001 8247 8255
12. J. Palacios, and C. Gamallo Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas Cancer Res. 58 1998 1344 1347
13. C. Gamallo, J. Palacios, G. Moreno, J. Calvo de Mora, A. Suarez, and A. Armas beta-catenin expression pattern in stage I and II ovarian carcinomas: relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome Am. J. Pathol. 155 1999 527 536
14. K. Wright, P. Wilson, S. Morland, I. Campbell, M. Walsh, T. Hurst, B. Ward, M. Cummings, and G. Chenevix-Trench beta-catenin mutation and expression analysis in ovarian cancer: exon 3 mutations and nuclear translocation in 16% of endometrioid tumours Int. J. Cancer 82 1999 625 629
15. G. Moreno-Bueno, C. Gamallo, L. Perez-Gallego, J.C. de Mora, A. Suarez, and J. Palacios beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas Diagn Mol. Pathol. 10 2001 116 122
16. U. Saran, F. Arfuso, N. Zeps, and A. Dharmarajan Secreted frizzled-related protein 4 expression is positively associated with responsiveness to cisplatin of ovarian cancer cell lines in vitro and with lower tumour grade in mucinous ovarian cancers BMC Cell Biol. 13 2012 25
17. F. Jacob, K. Ukegjini, S. Nixdorf, C.E. Ford, J. Olivier, R. Caduff, J.P. Scurry, R. Guertler, D. Hornung, R. Mueller, D.A. Fink, N.F. Hacker, and V.A. Heinzelmann-Schwarz Loss of secreted frizzled-related protein 4 correlates with an aggressive phenotype and predicts poor outcome in ovarian cancer patients PLoS One 7 2012 e31885
18. C.E. Ford, E. Jary, S.S. Ma, S. Nixdorf, V.A. Heinzelmann-Schwarz, and R.L. Ward The Wnt gatekeeper SFRP4 modulates EMT, cell migration and downstream Wnt signalling in serous ovarian cancer cells PLoS One 8 2013 e54362
19. H.Y. Su, H.C. Lai, Y.W. Lin, C.Y. Liu, C.K. Chen, Y.C. Chou, S.P. Lin, W.C. Lin, H.Y. Lee, and M.H. Yu Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway Int. J. Cancer 127 2010 555 567
20. J. Zhu, S. Zhang, L. Gu, and W. Di Epigenetic silencing of DKK2 and Wnt signal pathway components in human ovarian carcinoma Carcinogenesis 33 2012 2334 2343
21. A. You, E. Fokas, L.F. Wang, H. He, B. Kleb, D. Niederacher, R. Engenhart-Cabillic, and H.X. An Expression of the Wnt antagonist DKK3 is frequently suppressed in sporadic epithelial ovarian cancer J. Cancer Res. Clin. Oncol. 137 2011 621 627
22. C. Peng, X. Zhang, H. Yu, D. Wu, and J. Zheng Wnt5a as a predictor in poor clinical outcome of patients and a mediator in chemoresistance of ovarian cancer Int. J. Gynecol. Cancer 21 2011 280 288
23. S. Yoshioka, M.L. King, S. Ran, H. Okuda, J.A. MacLean 2nd, M.E. McAsey, N. Sugino, L. Brard, K. Watabe, and K. Hayashi WNT7A regulates tumor growth and progression in ovarian cancer through the WNT/beta-catenin pathway Mol. Cancer Res. 10 2012 469 482
24. L. Rosano, R. Cianfrocca, P. Tocci, F. Spinella, V. Di Castro, V. Caprara, E. Semprucci, G. Ferrandina, P.G. Natali, and A. Bagnato Endothelin A receptor/beta-arrestin signaling to the Wnt pathway renders ovarian cancer cells resistant to chemotherapy Cancer Res. 74 2014 7453 7464
25. L. Rosano, R. Cianfrocca, F. Spinella, V. Di Castro, M.R. Nicotra, A. Lucidi, G. Ferrandina, P.G. Natali, and A. Bagnato Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells Clin. Cancer Res. 17 2011 2350 2360
26. H. Zhang, X. Jing, X. Wu, J. Hu, X. Zhang, X. Wang, P. Su, W. Li, and G. Zhou Suppression of multidrug resistance by rosiglitazone treatment in human ovarian cancer cells through downregulation of FZD1 and MDR1 genes Anticancer Drugs 26 2015 706 715
27. W.K. Chau, C.K. Ip, A.S. Mak, H.C. Lai, and A.S. Wong c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/beta-catenin-ATP-binding cassette G2 signaling Oncogene 32 2013 2767 2781
28. B.C. Behrens, T.C. Hamilton, H. Masuda, K.R. Grotzinger, J. Whang-Peng, K.G. Louie, T. Knutsen, W.M. McKoy, R.C. Young, and R.F. Ozols Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues Cancer Res. 47 1987 414 418
29. A.K. Azad, S. Chakrabarti, Z. Xu, S.T. Davidge, and Y. Fu Coiled-coil domain containing 3 (CCDC3) represses tumor necrosis factor-alpha/nuclear factor kappaB-induced endothelial inflammation Cell Signal 26 2014 2793 2800
30. Y. Fu, H. Sies, and X.G. Lei Opposite roles of selenium-dependent glutathione peroxidase-1 in superoxide generator diquat- and peroxynitrite-induced apoptosis and signaling J. Biol. Chem. 276 2001 43004 43009
31. S.H. Barghout, N. Zepeda, K. Vincent, A.K. Azad, Z. Xu, C. Yang, H. Steed, L.M. Postovit, and Y. Fu RUNX3 contributes to carboplatin resistance in epithelial ovarian cancer cells Gynecol. Oncol. 138 2015 647 655
32. H. Clevers, and R. Nusse Wnt/beta-catenin signaling and disease Cell 149 2012 1192 1205
33. P. Polakis The oncogenic activation of beta-catenin Curr. Opin. Genet. Dev. 9 1999 15 21
34. K. Ewan, B. Pajak, M. Stubbs, H. Todd, O. Barbeau, C. Quevedo, H. Botfield, R. Young, R. Ruddle, L. Samuel, A. Battersby, F. Raynaud, N. Allen, S. Wilson, B. Latinkic, P. Workman, E. McDonald, J. Blagg, W. Aherne, and T. Dale A useful approach to identify novel small-molecule inhibitors of Wnt-dependent transcription Cancer Res. 70 2010 5963 5973
35. L. Farrand, S. Byun, J.Y. Kim, A. Im-Aram, J. Lee, S. Lim, K.W. Lee, J.Y. Suh, H.J. Lee, and B.K. Tsang Piceatannol enhances cisplatin sensitivity in ovarian cancer via modulation of p53, X-linked inhibitor of apoptosis protein (XIAP), and mitochondrial fission J. Biol. Chem. 288 2013 23740 23750
36. L. Farrand, J.Y. Kim, S. Byun, A. Im-Aram, J. Lee, J.Y. Suh, K.W. Lee, H.J. Lee, and B.K. Tsang The Diarylheptanoid Hirsutenone Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin via Modulation of Apoptosis-inducing Factor and X-linked Inhibitor of Apoptosis J. Biol. Chem. 289 2014 1723 1731
37. J. Drake, A.M. Shearwood, J. White, R. Friis, N. Zeps, A. Charles, and A. Dharmarajan Expression of secreted frizzled-related protein 4 (SFRP4) in primary serous ovarian tumours Eur. J. Gynaecol. Oncol. 30 2009 133 141
38. J. Madore, F. Ren, A. Filali-Mouhim, L. Sanchez, M. Kobel, P.N. Tonin, D. Huntsman, D.M. Provencher, and A.M. Mes-Masson Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma J. Pathol. 220 2010 392 400
39. L. Bodnar, A. Stanczak, S. Cierniak, M. Smoter, M. Cichowicz, W. Kozlowski, C. Szczylik, M. Wieczorek, and M. Lamparska-Przybysz Wnt/beta-catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer J. Ovarian Res. 7 2014 16
40. R.J. Burkhalter, S.D. Westfall, Y. Liu, and M.S. Stack Lysophosphatidic Acid Initiates Epithelial to Mesenchymal Transition and Induces beta-Catenin-mediated Transcription in Epithelial Ovarian Carcinoma J. Biol. Chem. 290 2015 22143 22154
41. H. Zhao, W. Wei, Y. Sun, J. Gao, Q. Wang, and J. Zheng Interference with the expression of beta-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model DNA Cell Biol. 34 2015 55 62
42. A.B. Nagaraj, P. Joseph, O. Kovalenko, S. Singh, A. Armstrong, R. Redline, K. Resnick, K. Zanotti, S. Waggoner, and A. DiFeo Critical role of Wnt/beta-catenin signaling in driving epithelial ovarian cancer platinum resistance Oncotarget 6 2015 23720 23734
43. J.N. Anastas, and R.T. Moon WNT signalling pathways as therapeutic targets in cancer Nat. Rev. Cancer 13 2013 11 26
44. R.C. Arend, A.I. Londono-Joshi, R.S. Samant, Y. Li, M. Conner, B. Hidalgo, R.D. Alvarez, C.N. Landen, J.M. Straughn, and D.J. Buchsbaum Inhibition of Wnt/beta-catenin pathway by niclosamide: a therapeutic target for ovarian cancer Gynecol. Oncol. 134 2014 112 120